Okay, let's tackle this question. The patient is a 45-year-old male with proliferative diabetic retinopathy (PDR) and vitreomacular traction (VMT). The question is asking about the treatment options.

First, I need to recall the treatment for PDR and VMT. PDR is a complication of diabetes where abnormal blood vessels grow in the retina. Treatment options include laser photocoagulation, anti-VEGF injections, and sometimes surgery like vitrectomy. Vitreomacular traction is when the vitreous is abnormally adherent to the macula, causing distortion. Treatment for VMT can involve anti-VEGF to reduce traction or vitrectomy if it's severe.

Now, the correct answer here would likely be a treatment that addresses both conditions. Since the options aren't provided, I need to think about what the standard treatments are. For PDR, panretinal photocoagulation (PRP) is a mainstay. For VMT, anti-VEGF agents like ranibizumab or aflibercept might be used first to reduce traction. If that doesn't work, vitrectomy is the next step. So, if the options include anti-VEGF injections or vitrectomy, those would be correct. The wrong options might include things like systemic steroids, which aren't typically used for VMT or PDR, or maybe laser alone without addressing the traction.

Wait, the correct answer here is probably a combination of anti-VEGF and vitrectomy. But depending on the options given, the best choice would be the one that addresses both conditions. Let me check the standard approach. In PDR with VMT, the treatment is usually PRP with adjunctive anti-VEGF to reduce neovascularization and traction. If VMT persists, vitrectomy is necessary. So the correct answer would include PRP and anti-VEGF. Alternatively, if the options separate them, the correct answer would be the one that includes both steps. The incorrect options might be things like focal laser, which is for diabetic macular edema, or systemic treatments that aren't indicated here.

So, putting this together, the core concept is the management of PDR with VMT. The correct treatment would involve addressing both the proliferative aspect with PRP and the vitreomacular traction with anti-VEGF or vitrectomy. The wrong options would be treatments not indicated for these conditions. The clinical pearl is that PRP is the first-line for PDR, and anti-VEGF is used for VMT. The correct answer here would be the option that includes PRP and anti-VEGF.

**Core Concept**
Proliferative diabetic retinopathy (PDR) involves neovascularization and vitreoretinal traction, while vitreomacular traction (VMT) causes macular distortion due to persistent vitreomacular adhesion. Treatment must address both conditions to prevent vision loss. Key interventions include anti-VEGF agents and vitrectomy.

**Why the Correct Answer is Right**
The primary treatment for PDR is **panretinal photocoagulation (PRP)** to reduce hypoxia-driven neovascularization. For VMT, **anti-VEGF injections** (e.g., ranibizumab) are first-line to decrease vitreoretinal ad

✓ Correct Answer: B. Vitrectomy with endophotocoagulation